You have no items in your shopping cart.

Merck & Company: Product KL-798
Frey, Sherwood C. Jr.; Bodily, Samuel E. Case QA-0582 / Published July 9, 2001 / 4 pages.
Format Price Quantity Select
PDF Download
$6.95
Printed Black & White Copy
$7.25

Product Overview

Merck has been approached by a small biotech research firm with the proposal that Merck buy the rights to a new drug that promises to treat obesity and lower cholesterol. The drug is in the middle of phase I of the FDA approval process. Pat Harlow, the chief licensing officer, has been leading Merck's investigation team. A meeting is scheduled for tomorrow at which Merck's response to the offer will be drafted.


  • Videos List

  • Overview

    Merck has been approached by a small biotech research firm with the proposal that Merck buy the rights to a new drug that promises to treat obesity and lower cholesterol. The drug is in the middle of phase I of the FDA approval process. Pat Harlow, the chief licensing officer, has been leading Merck's investigation team. A meeting is scheduled for tomorrow at which Merck's response to the offer will be drafted.

  • Learning Objectives